|
Thursday 4th May 2023 |
Text too small? |
AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023. The release will be issued at around 09:00.
This will be followed by a presentation by management at 10:00 by teleconference. The presentation material which will be referred to by management will be issued at around 09:00 and will also be available on the company’s website aftpharm.com.
To attend the conference call you will need to use the pre-registration link below. Once you have completed this you will be provided with dial in details and a unique pin code.
Registration Link: AFT results presentation FY2023
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.
For more information:
Investors Media
Malcolm Tubby Richard Inder
CFO, AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: 021 645 643
Email: malcolm@aftpharm.com Email: richard@theproject.co.nz
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com
No comments yet
KPG - Kiwi Property Green Bond offer closed
PFI - Capital Change Notice - FY27 LTI Scheme Grant
IKE - 1H FY27 Performance Update
SUM - Summerset Appoints Sue Matthews as Independent Director
GNE - FY27 Q1 Performance Report
FPH - F&P Healthcare statement regarding cyber incident
HGH - Heartland Group confirms leadership endorsements
October 22nd Morning Report
VCT - Operational Performance for the 3 months ended 30 Sept 2026
SKL - Skellerup with strong start, forecasts growth for FY27